232 results on '"Asimakopoulos, Fotis"'
Search Results
2. Emerging roles for tumor stroma in antigen presentation and anti-cancer immunity.
3. Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
4. Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responses
5. Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer
6. Versican in Tumor Progression, Tumor–Host Interactions, and Cancer Immunotherapy
7. Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model
8. Versican in the Tumor Microenvironment
9. Versican in Tumor Progression, Tumor–Host Interactions, and Cancer Immunotherapy
10. Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice
11. Correction: Emerging roles for tumor stroma in antigen presentation and anti-cancer immunity
12. Mechanisms of Resistance in Multiple Myeloma
13. P-376 Genomic and transcriptional profiling stratifies myeloma models into two clusters with distinct risk signatures and drug responses
14. Supplemental Tables 1 - 2, Figures 1 - 3 from Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma
15. Data from Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma
16. Heart-liver-kidney transplantation for AL amyloidosis using normothermic recovery and storage from a donor following circulatory death: Short-term outcome in a first-in-world experience
17. Genomic and Transcriptional Profiling Stratifies Vq Myeloma Lines into Two Clusters with Distinct Risk Signatures and Drug Responses
18. 981 Peritumoral stromal remodeling licenses cDC1 through CD40 to elicit T-cell inflammation
19. Single-molecule analysis reveals widespread structural variation in multiple myeloma
20. Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myeloma
21. Matrix proteoglycans in tumor inflammation and immunity
22. Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment
23. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis
24. Mechanisms of Resistance in Multiple Myeloma
25. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
26. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis
27. Ponatinib for RAS-Driven Multiple Myeloma: Efficacy in the High-Risk VQ Myeloma Model
28. Differential Regulation of TNFα and IL-6 Expression Contributes to Immune Evasion in Prostate Cancer
29. Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment
30. 936 Stromal remodeling regulates dendritic cell abundance in the tumor microenvironment
31. Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network
32. Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myeloma.
33. The Gut Microbiome Is Shaped By Pre-Transplant Dietary Intake, Damaged By Broad-Spectrum Antibiotic Exposure, and Is Associated with Response to Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
34. Targeted treatment of multiple myeloma with a radioiodinated small molecule radiopharmaceutical
35. Expression of Nras Q61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice
36. Developing Novel Targeted Therapies Using the High-Risk Vq Myeloma Model
37. MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages
38. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells
39. Abstract 5733: Versican proteolytic fragments (matrikines) synergize with STING agonists to elicit robust anti-tumor CD8+ T cell responses
40. Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity
41. VCAN accumulation and proteolysis as predictors of T lymphocyte-excluded and permissive tumor microenvironments.
42. Impact of Antibiotics on Gut Microbiota Diversity and the Results of a Prospective Dietary Assessment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
43. Versican Proteolytic Fragments (Matrikines) Regulate the Intratumoral Dendritic Cell Milieu In Vivo: Implications for in Situ Tumor Vaccination
44. Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)
45. Impact of Antibiotics on Gut Microbiota Diversity and the Results of a Prospective Dietary Assessment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
46. Abstract 1904: Versican production is driven by both epithelial and stromal cells in pancreatic cancer
47. Abstract 3209: BLZ945 and anti-PD-1 combination immunotherapy modulates the immune landscape in pancreatic ductal adenocarcinoma
48. Abstract 1909: Stromal cell driven proteolysis of versican is limited by epithelial cells in pancreatic ductal adenocarcinoma
49. Abstract 4583: Versican accumulation and proteolysis in neuroendocrine tumors
50. Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.